论文部分内容阅读
目的探讨肝细胞癌(hepatocellular carcimona,HCC)患者外周血浆和肿瘤组织中RASSF1A基因甲基化及其临床意义。方法应用甲基化特异性PCR(MSP)检测36例HCC患者血浆及其对应癌组织中的RASSF1A基因启动子甲基化状态,并分析其与临床参数的关系。结果癌组织和外周血浆中RASSF1A基因甲基化率分别为83.3%(30/36)和61.1%(22/36),二者相关系数为r=0.561(P=0.0004)。外周血浆和肿瘤组织中RASSF1A基因甲基化率与患者性别、年龄、HBV/HCV感染、肝硬化、肿瘤大小、AFP水平、肿瘤病理分级及临床分期、有无癌栓及是否为复发病例等之间无统计学相关性。以AFP≥400 ug/L为阳性,本组病例AFP阳性率为44.4%;以AFP≥20 ug/L为阳性,本组病例阳性率为69.4%。全部患者中,血浆RASSF1A基因甲基化检出率为61.1%,AFP联合血浆RASSF1A基因甲基化检测HCC的检出率为75%(27/36)。结论 HCC患者血浆和肿瘤组织中RASSF1A基因甲基化率有良好的一致性。血浆DNA甲基化联合AFP检测对HCC早期诊断具有一定意义。癌组织和血浆中基因甲基化改变与各临床参数无相关性。
Objective To investigate the methylation status of RASSF1A gene in peripheral blood plasma and tumor tissues of patients with hepatocellular carcinoma (HCC) and its clinical significance. Methods Methylation-specific PCR (MSP) was used to detect the promoter methylation status of RASSF1A gene in plasma and corresponding cancerous tissues of 36 patients with HCC, and its relationship with clinical parameters was analyzed. Results The methylation rates of RASSF1A gene in cancer tissue and peripheral plasma were 83.3% (30/36) and 61.1% (22/36), respectively, with a correlation coefficient of r = 0.561 (P = 0.0004). The methylation rates of RASSF1A gene in peripheral blood plasma and tumor tissues were related to patient’s gender, age, HBV / HCV infection, cirrhosis, tumor size, AFP level, tumor pathological grade and clinical stage, tumor thrombus and recurrence No statistical correlation between. The AFP≥400 ug / L was positive, the positive rate of AFP in this group was 44.4%. The positive rate of AFP≥20 ug / L was 69.4% in this group. The methylation detection rate of plasma RASSF1A gene was 61.1% in all patients, and 75% (27/36) in detection of HCC by methylation of AFP combined with plasma RASSF1A gene. Conclusion The methylation rates of RASSF1A gene in plasma and tumor tissues of patients with HCC are in good agreement. Plasma DNA methylation combined with AFP detection of HCC early diagnosis has some significance. There was no correlation between methylation changes of cancer tissue and plasma and clinical parameters.